Editorial

Amiodarone-induced Pulmonary Hemorrhage

Authors: Sonal Singh, MD

Abstract

Amiodarone is a widely prescribed anti-arrhythmic for atrial and ventricular arrhythmias. The adverse effect profile of amiodarone is diverse, involving the cardiac, thyroid, pulmonary, hepatic, gastrointestinal, ocular, neurologic and dermatological systems.1 However, the most severe and potentially life threatening of these side effects is the development of pulmonary toxicity.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69–110.
 
2. Ravishankar R, Samuels LE, Kaufman MS, et al. Amiodarone-associated hemoptysis. Am J Med Sci1998;316:390–392.
 
3. Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. Can J Cardiol 2000;16:1435–1440.
 
4. Martin II, WJ Rosenow EC III. Amiodarone pulmonary toxicity: recognition and pathogenesis (part I).Chest 1988;93:1067–1075.
 
5. Handschin AE, Lardinois D, Schneiter D, et al. Acute amiodarone-induced pulmonary toxicity following lung resection. Respiration 2003;70:310–312.
 
6. Morady F, Sauve MJ, Malone P, et al. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1983;52:975–979.
 
7. Conte SC, Pagan V, Murer B. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: clinical, radiological and histological pattern. Monaldi Arch Chest Dis 1997;52:24–26.
 
8. Rodriguez-Garcia JL, Garcia-Nieto JC, Ballesta F, et al. Pulmonary mass and multiple lung nodules mimicking a lung neoplasm as amiodarone-induced pulmonary toxicity. Eur J Intern Med 2001;12:372–376.
 
9. Bernal Morell E, Hernandez Madrid A, Marin Marin I, et al. Multiple pulmonary nodules and amiodarone: KL-6 as a new diagnostic tool. Rev Esp Cardiol 2005;58:447–449.
 
10. Goldstein I, Topilsky M, Segev D, et al. Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. Chest 1997;111:1446–1447.
 
11. Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002;89:896–898.
 
12. Ulrik CS, Aldershvile J. Early diagnosis of amiodarone-induced pulmonary toxicity: Are repeated lung function tests of any value? Ugeskr Laeger 1996;158:3445–3447.
 
13. Ulrik CS, Backer V, Aldershvile J, Pietersen AH. Serial pulmonary function tests in patients treated with low-dose amiodarone. Am Heart J 1992;123:1550–1554.
 
14. Oyama N, Oyama N, Yokoshiki H, et al. Detection of amiodarone-induced pulmonary toxicity in supine and prone positions: high-resolution computed tomography study. Circ J 2005;69:466–470.
 
15. Martin II, WJ Standing JE. Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J Pharmacol Exp Ther1988;244:774–779.
 
16. Endoh Y, Hanai R, Uto K, et al. KL-6 as a potential new marker for amiodarone-induced pulmonary toxicity. Am J Cardiol 2000;86:229–231.
 
17. Endoh Y, Hanai R, Uto K, et al. Diagnostic accuracy of KL-6 as a marker of amiodarone-induced pulmonary toxicity. Pacing Clin Electrophysiol 2000;23:2010–2013.
 
18. Umetani K, Abe M, Kawabata K, et al. SP-D as a marker of amiodarone-induced pulmonary toxicity.Intern Med 2002;41:709–712.
 
19. Devine PL, Siebert WJ, Morton SL, et al. Serum mucin antigen (CASA) as a marker of amiodarone-induced pulmonary toxicity. Dis Markers 1998;14:169–175.
 
20. Jessurun GA, Boersma WG, Crijns HJ. Amiodarone-induced pulmonary toxicity: predisposing factors, clinical symptoms and treatment. Drug Saf 1998;18:339–344.
 
21. Iskandar S, Abi-Saleh B, Keith R, et al. Amiodarone-induced alveolar hemorrhage. South Med J2006;99:383–387.
 
22. Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest 1994;105:305–306.